Paula Debroy
University of Texas at Austin
13 Papers
Paula Debroy is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Medicine & Fatty liver. The author has an hindex of 4, co-authored 8 publications. Previous affiliations of Paula Debroy include Jacobi Medical Center & University of Texas Health Science Center at Houston.
Chat about Author
Papers
Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
Jordan E. Lake,Kunling Wu,Sara H Bares,Paula Debroy,Catherine Godfrey,John R. Koethe,Grace A. McComsey,Frank J. Palella,Katherine Tassiopoulos,Kristine M. Erlandson +9 more
TL;DR: Yearly weight gain increased following switch to INSTI, particularly for women, blacks and persons age ≥60, and concomitant increases in waist circumference suggest that this weight gain is associated with an increase in fat mass.
166
Lean mass declines consistently over 10 years in people living with HIV on antiretroviral therapy, with patterns differing by sex.
Paula Debroy,Jordan E. Lake,Myung Sim,Kristine M. Erlandson,Julian Falutz,Carla M. Prado,Todd T. Brown,Giovanni Guaraldi,Metabolic Cohort Team Tmh +8 more
TL;DR: ALM steadily declined over time in this cohort of PLWH on ART that included a large number of women, and HIV- and ART-specific risk factors emerged that varied by sex.
16
Changes in central adipose tissue after switching to integrase inhibitors.
Paula Debroy,Han Feng,Hongyu Miao,Jovana Milic,Guido Ligabue,Stefano Draisci,Giulia Besutti,Federica Carli,Marianna Menozzi,Cristina Mussini,Giovanni Guaraldi,Jordan E. Lake +11 more
- 01 Nov 2020
TL;DR: In this article, the long-term effect of INSTI-based regimens on adipose tissue (AT) was investigated and it was shown that INSTIs are associated with excess weight gain.
15
A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial
Jordan E. Lake,Ana N. Hyatt,Han Feng,Paula Debroy,Aaren Kettelhut,Hongyu Miao,Liming Peng,Shalender Bhasin,Nahid J Rianon,Todd M. Brown,Nicholas T. Funderburg +10 more
TL;DR: In this paper , the authors evaluated the 48-week safety/tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs continued ART in TW on GAHT.
Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus
Jordan E. Lake,Ruibin Wang,Benjamin W. Barrett,Emily R. Bowman,Ana N. Hyatt,Paula Debroy,Jury Candelario,Linda A. Teplin,Kaitlin Bodnar,Heather S. McKay,Michael Plankey,Todd M. Brown,Nicholas T. Funderburg,Judith S. Currier +13 more
TL;DR: Compared to matched cisgender men, trans women have altered profiles of biomarkers associated with systemic inflammation and CVD.
5